anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We aim to understand the effects of hydration changes on athletes' neuromuscular performance, on body water compartments, fat-free mass hydration and hydration biomarkers and to test the effects of the intervention on the response of acute dehydration in the hydration indexes. The H2OAthletes study (clinicaltrials.gov ID: NCT05380089) is a randomised controlled trial in thirty-eight national/international athletes of both sexes with low total water intake (WI) (i.e. < 35·0 ml/kg/d). In the intervention, participants will be randomly assigned to the control (CG, n 19) or experimental group (EG, n 19). During the 4-day intervention, WI will be maintained in the CG and increased in the EG (i.e. > 45·0 ml/kg/d). Exercise-induced dehydration protocols with thermal stress will be performed before and after the intervention. Neuromuscular performance (knee extension/flexion with electromyography and handgrip), hydration indexes (serum, urine and saliva osmolality), body water compartments and water flux (dilution techniques, body composition (four-compartment model) and biochemical parameters (vasopressin and Na) will be evaluated. This trial will provide novel evidence about the effects of hydration changes on neuromuscular function and hydration status in athletes with low WI, providing useful information for athletes and sports-related professionals aiming to improve athletic performance.
Control group will have a full thickness flap, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
OBJECTIVE: Solitary fibrous tumors (SFTs) and haemangiopericytomas (HPCs) are rare mesenchymal tumors in central nervous system (CNS). Although progressed recognition to the diagnosis and treatment of SFT/HPCs, it still remains many confusions regarding on its occurrence, aggressive evolution, malignant transformation, dedifferentiation phenomenon, distant metastasis and unpredictable propensity.
PATIENTS AND METHODS: Seventeen cases of CNS SFT/HPCs who underwent surgical treatment from January 2010 to December 2020 were collected in the authors' institute. Clinical, radiological, pathological data and followup details were reviewed in all cases.
RESULTS: The age of this series was 41-73 years old. Seven cases located subtentorially, five cases originated from middle skull base and four in supratentorial. MRI shows iso-signal intensity on T1WI, and heterogeneous slightly long/short signal on T2WI. There is significant contrast after gadolinium-enhancement. It is easy to be misdiagnosed before surgery. The positive rate of nuclear STAT6 is 94.12%, higher than CD34 (87.5%). Eight patients were grade I, eight grade II and one in grade III. Five cases developed tumor relapse, in which two cases had local intracranial recurrence combined with dissemination and metastasis of cerebrospinal fluid in the spinal canal, accompanied by pathological malignant transformation, and another one occurred blood metastasis.
CONCLUSIONS: CNS SFT/HPCs are rare intracranial tumors with unpredictable propensity. Gross total resection is critical to its overall clinical prognosis. Given its potential recurrence and malignant transition, adjuvant radiotherapies are recommended when necessary, and long-term follow-up is indispensable. The underlying molecular biological mechanisms are still needed to be further exploration.
* In male and female rats, parathyroid hormone caused an increase in the incidence of osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was dependent on parathyroid hormone dose and treatment duration. This effect was observed at parathyroid hormone exposure levels ranging from 3 to 71 times the exposure levels in humans receiving a 100 mcg dose of NATPARA. These data could not exclude a risk to humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
  * Because of a potential risk of osteosarcoma, use NATPARA only in patients who cannot be well-controlled on calcium and active forms of vitamin D alone and for whom the potential benefits are considered to outweigh this potential risk [see Indications and Usage (1), Warnings and Precautions (5.1)].
  * Avoid use of NATPARA in patients who are at increased baseline risk for osteosarcoma, such as patients with Paget's disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, patients with hereditary disorders predisposing to osteosarcoma or patients with a prior history of external beam or implant radiation therapy involving the skeleton [see Warnings and Precautions (5.1)].
  * Because of the risk of osteosarcoma, NATPARA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the NATPARA REMS Program [see Warnings and Precautions (5.2)].
Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization. The resulting microbubble suspension may be centrifuged to further concentrate the microbubbles. The resulting concentrated LOM suspension preferably has an oxygen content ranging from 50 to 99% (vol). Prior to administration to a patient, the viscosity of the LOM suspension may be reduced to the desired viscosity, preferably similar to the viscosity of the patient's blood. The resulting LOM formulation typically has an oxygen concentration ranging from 65 to 80% (vol). The microbubbles are formed from one or more lipids, preferably one or more phospholipids, most preferably DSPC, and preferably also contain one or more stabilizing agents/excipients, preferably cholesterol.
Methods of enhancing epithelial cell proliferation are disclosed. The methods comprise the step of contacting epithelial cells with a compound that binds to reovirus type 3 receptor. Methods of treating an individual susceptible to or suffering from a condition, disease or disorder characterized by insufficient proliferation of epithelial cells are disclosed. The methods comprise the steps of identifying such individuals and administering to them a therapeutically effect amount of compound that binds to reovirus type 3 receptor and thereby enhances proliferation of epithelial cells. Methods of treating individuals suffering from wounds that involve epithelial cells are disclosed. The methods comprise the steps of identifying such individuals and administering to them a therapeutically effect amount of compound that binds to reovirus type 3 receptor and thereby enhances proliferation of epithelial cells.\!
This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndrome). AIDS is one of the most serious viral infections of our time. It is believed that all persons who contract HIV will eventually develop AIDS. Because of this, we are trying to develop new ways to prevent infection with HIV.

Vaccines have been very successful in preventing or decreasing the symptoms of a number of other viral infections such as hepatitis B, polio, and measles. Viral vaccines work by causing a person's immune system to make antibodies and immune cells against the virus or to "respond" to the virus. Because of the success with other viral infections, scientists are trying to develop a successful vaccine for HIV.

The vaccine that will be tested in this study has been prepared from a small part of the HIV. The part of the HIV used in this vaccine is the "envelope" or coating part of the virus. Because only this one part of the virus is used in the vaccine, the vaccine cannot cause HIV infection. The "envelope" part of HIV has been put into another virus, the vaccinia virus. The vaccinia virus has been used as a vaccine for many decades in millions of people and is the vaccine that eliminated the disease known as smallpox (i.e. smallpox vaccine). The smallpox vaccine is a licensed and effective vaccine. Making a new vaccine by putting part of a different virus into the smallpox vaccine (also known as vaccinia virus) is called a "recombinant" vaccinia virus vaccine. Our new recombinant vaccine product is called PolyEnv1. In this study, researchers will evaluate how well the vaccine is tolerated, how much vaccine should be given, and determine if any side effects occur in response to the vaccination.
Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2  in vivo  and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been disovered that Erbin plays a role in the myelination of neurons of the peripheral nervouse system.
PROBLEM TO BE SOLVED: To make it possible to evaluate the suppressing action of regression period in a hair cycle by measuring the total amounts of mononucleosome and oligonucleosome in trichocyst-originated cell. SOLUTION: The back skins of C3H mice are shaved, about five mice are used for each sample from about tenth day, the skins of parts for test are continuously coated twice in the morning and evening with about each 0.2ml for ten days. After the coating, they are butchered, the hairs of the parts for test of the samples are collected, and trypsin-treaded. Incubation buffer is added to the obtained cells of predetermined quantity, steadily left to stand for 30min at about 4 deg.C, centrifugally separated, and the part of supernatant is sampled. The sample thinned to about ten times of about 100μl is added to plate coated with antihistone antibody, steadily left to stand for about 90min, and then the plate is cleaned. Then, the same amount of anti-DNA-peroxidase antibody is similarly added, and cleaned.  Eventually, the substrate solution of the peroxidase of about 100μl is added, the absorbance is measured in the wavelength of 405nm, and the total amount of mononucleosome and oligonucleosome is obtained.
Neuromyelitis optica (NMO) is an autoimmune inflammatory disease that primarily affects the optic nerve and spinal cord within the central nervous system (CNS). Acute astrocyte injury caused by autoantibodies against aquaporin 4 (NMO-IgG) is a well-established key factor in the pathogenesis, ultimately leading to neuronal damage and patient disability. In addition to these humoral immune processes, numerous innate immune cells were found in the acute lesions of NMO patients. However, the origin and function of these innate immune cells remain unclear in NMO pathogenesis. Therefore, this study aims to analyze the origin and functions of these innate immune cells in an NMO-like mouse model and evaluate their role in the pathophysiology of NMO. The expression of Tmem119 on Iba1 + cells in brain tissue disappeared immediately after the injection of NMO-IgG + human complement mixture, while the expression of P2ry12 remained well-maintained at 1 day after injection. Based on these observations, it was demonstrated that monocytes infiltrate the brain during the early stages of the pathological process and are closely associated with the inflammatory response through the expression of the proinflammatory cytokine IL-1β. Understanding the variations in the expression patterns of P2ry12, Tmem119, and other markers could be helpful in distinguishing between these cell types and further analyzing their functions. Therefore, this research may contribute to a better understanding of the mechanisms and potential treatments for NMO.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new sulfoneamidocarboxamides of the general formula (I) where values A, Y, X are indicated in p. 1 of the invention claim. Also, the invention describes their hydrates and physiologically acceptable salts and a pharmaceutical composition based on compounds of the formula (I). Compounds and composition show an antiaggregate and anticoagulant activity and capability to inhibit amidolytic activity of thrombin. EFFECT: new compounds indicated above, valuable pharmacological properties of compounds. 17 cl, 2 tbl, 73 ex
OBJECTIVE: The primary objective of this study is to examine the distribution and prognostic implications of serum vitamin D levels among individuals diagnosed with primary hepatic carcinoma (PHC) attributable to hepatitis B virus (HBV) infection.
METHODS: A total of 345 patients diagnosed with HBV infection were enrolled in our hospital between August 2014 and October 2020. Among these, 144 individuals were diagnosed with chronic hepatitis B (CHB), 66 individuals were diagnosed with HBV-related hepatic cirrhosis (HBV cirrhosis), and 135 individuals were diagnosed with HBV-related PHC (HBV-PHC). Peripheral serum levels of vitamin D were measured. Patients with cirrhosis underwent examination using the Child-Pugh grading system, and the mortality rates at 1-year and 3-year intervals for patients with HBV-PHC were analyzed.
RESULTS: Vitamin D levels in peripheral serum in the CHB group, HBV cirrhosis group, and HBV-PHC group exhibited varying degrees of reduction compared to healthy individuals. Significant differences were observed between the three groups (F = 4.02, P = 0.019). No significant difference was observed in vitamin D levels between different Child-Pugh grades within the HBV cirrhosis group (F = 0.89, P = 0.417). However, significant differences were observed in vitamin D levels between different Child-Pugh grades within the HBV-PHC group (F = 4.84, P = 0.009). There was no significant difference in 1-year and 3-year mortality rates between patients diagnosed with HBV-PHC and with varying vitamin D levels (P > 0.05).
CONCLUSIONS: Vitamin D levels decreased to varying degrees in patients diagnosed with CHB, HBV cirrhosis, and PHC. This decrease was well correlated with disease progression (HBV-PHC group < HBV cirrhosis group < CHB group). In cases where hepatic function was comparable, there was no discernible correlation between serum vitamin D level and mortality rates from PHC.
Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To make a doctor able to smoothly introduce an electronic clinical chart system in place of a conventional handwriting system, by enabling the doctor to input a writing state and the image of a completed clinical chart while grasping them like a paper clinical chart. SOLUTION: A processor 12 stores the format data stored in a clinical chart format storage 15 and the diagnostic data inputted via an input device 11 in a storage 13 after a doctor synthesized both data and also shows these synthetic data on a display device 17. A clinical chart format editing device 14 corrects or changes a clinical chart format on a display screen, and a user (doctor) can freely change the format of the clinical chart. The edited format of the clinical chart is stored in the storage 15. In other words, the format of a clinical chart is stored and then synthesized with the input diagnostic contents to be separately stored. At the same time, the stored contents are outputted onto the display screen and then a clinical chart of the same image as that of the displayed clinical chart is printed out.
BACKGROUND: We investigated the prevalence and effects of hazardous alcohol consumption on perioperative complications in cardiac surgery patients. Preoperative hazardous alcohol consumption has been associated with an increased risk of postoperative complications in noncardiac patient populations.
METHODS: We retrospectively collected data from the Finnish Intensive Care Consortium database and electronic patient records on all cardiac surgery patients treated in the intensive care units (ICUs) of Helsinki University Hospital (n = 919) during 2017. Data on preoperative alcohol consumption were routinely collected using the alcohol use disorder identification test consumption (AUDIT-C) questionnaire. We analyzed perioperative data and outcomes for any associations with hazardous alcohol consumption. Outcome measures were length of stay in the ICU, re-admissions to ICU, bleeding and infectious complications, and incidence of postoperative arrhythmias.
RESULTS: AUDIT-C scores were available for 758 (82.5%) patients, of whom 107 (14.1%) fulfilled the criteria for hazardous alcohol consumption (AUDIT-C score of 5/12 or higher for women and 6/12 or higher for men). Patients with hazardous alcohol consumption were younger, median age 59 (IQR 52.0-67.0) vs. 69.0 (IQR 63.0-74.0), p < .001, and more often men 93.5% vs. 71.9%, p < .001 than other patients and had an increased risk for ICU re-admissions [adjusted OR (aOR) 4.37 (95% CI, 1.60-11.95)] and severe postoperative infections aOR 3.26 (95% CI, 1.42-7.54).
CONCLUSION: Cardiac surgery patients with a history of hazardous alcohol consumption are younger than other patients and are predominantly men. Hazardous alcohol consumption is associated with an increased risk of severe postoperative infections and ICU re-admissions.
Objective: To understand the relationship between unhealthy lifestyle and hyperuricemia, as well as the modification effects of hypertension and dyslipidemia in occupational population and provide a theoretical basis for the prevention of hyperuricemia. Methods: A cross-sectional survey design was adopted, based on baseline data from the Southwest Occupational Population Cohort from China Railway Chengdu Group Co., Ltd., which included the population in 28 prefectures from Sichuan Province and Guizhou Province, and 33 districts (counties) from Chongqing Municipality between October and December 2021. This study collected the information about the demographics characteristics, lifestyles, and prevalence of chronic non-communicable diseases of the study subjects through questionnaire, physical measurement and laboratory biochemical test. The unhealthy lifestyle score was scored based on smoking, alcohol consumption, dietary patterns, physical activity, and low weight or overweight, with higher scores being associated with more unhealthy lifestyles. The multivariate logistic regression model was used to analyze the relationship between unhealthy lifestyle score, smoking, alcohol consumption, other factors and hyperuricemia, and the stratified analysis was used to explore the modification effect of hypertension and other diseases on the relationship between unhealthy lifestyle and hyperuricemia. Results: A total of 11 748 participants were included in this study, the prevalence of hyperuricemia was 34.4%. Multivariate logistic regression model showed that current/previous smoking, current/previous alcohol consumption and BMI abnormality were risk factors for hyperuricemia, and the unhealthy lifestyle score showed a "cumulative" effect on the risk for hyperuricemia, with higher score increasing the risk of hyperuricemia, and the OR increased from 1.64 (95%CI: 1.34-2.00) to 2.89 (95%CI: 2.39-3.50). Stratified analysis showed that unhealthy lifestyles had a greater impact on the risk for hyperuricemia in people with hypertension and dyslipidemia. Conclusions: The coexistence of multiple unhealthy lifestyles might increase the risk of hyperuricemia, and this effect was stronger in participants with hypertension and dyslipidemia. Timely correction of unhealthy lifestyles, and control of hypertension and dyslipidemia might reduce the risk for hyperuricemia.
The goal of this clinical trial is to learn about the role of traditional music therapy on burnout syndrome among healthcare workers. The investigators will collected about 80 participants, which eventually get divided into intervention (40 participants) and control (40 participants) group. Participants will get examined using Maslach Burnout Inventory-Human Service Survey for rating their burnout sydnrome. Before starting the intervention, both group will get assessed for their heart rate variability, IgA and T cell regulator level, and cortisol and endorphine level. After that, Intervention group will get traditional music therapy and educational video 3 session a week for about 4 weeks. And control group will only get educational video.

Both group will be assessed for their heart rate variability and their laboratory markers three times, 2 weeks after starting the intervention, right after finishing all intervention session on week 4, and 2 weeks after the intervention is done. Investigators will compare the results between control group (educational video only without any music therapy) and intervention group (traditional music therapy and educational video) to see if there are any role of traditional music therapy on burnout syndrome based on psychology-neuroautonom-immunology-endocrinology aspects.
The present invention provides a three-dimensional mesh-like hydrogel and a manufacturing method thereof. Firstly, water-soluble polymers are added into and uniformly mixed with a solvent, and hydrolyzed to form a sol, which is then transformed into a gel through a vacuum process. A three-dimensional mesh-like hydrogel is formed through polycondensation reaction. The three-dimensional mesh-like hydrogel is composed of water-soluble polymers. The water-soluble polymers include a group composed of sodium alginate and sodium carboxymethyl cellulose. The water-soluble polymers are interconnected to form a three-dimensional mesh structure. Thereby, the three-dimensional mesh-like hydrogel of the present invention serves as a gel coating agent. By using the high molecular polymer to form a three-dimensional mesh structure for encapsulating drugs, active ingredients can be more effectively protected to achieve a sustained-release effect, and furthermore, treatment effects can be increased and side effects of epidermal irritation can be reduced.
The present invention discloses a granular agent for benefiting qi and nourishing blood. The granular agent is characterized in that the granular agent is prepared from the raw materials of the following parts by weight: 304 parts to 336 parts of astragalus root, 304 parts to 336 parts of donkey-hide gelatin, 285 parts to 315 parts of pilose asiabell root, 95 parts to 105 parts of white peony root, 76 parts to 84 parts of angelica, 304 parts to 336 parts of hairyvein agrimonia herd, 152 parts to 168 parts of madder, 76 parts to 84 parts of finger citron, 76 parts to 84 parts of himalayan teasel root and a proper amount of auxiliary material. The present invention also discloses a preparation method of the granular agent for benefiting qi and nourishing blood. The granular agent for benefiting qi and nourishing blood of the present invention has the effects of benefiting qi and nourishing blood. The effective rate for patients with the syndrome of deficiency of both qi and blood, such as profuse menstruation, menostaxis, advanced menstruation, etc., caused by insertion of an intra-uterine contraception ring, implantation under skin, other family planning operations, etc. can reach 89.29%, and the contraception effect can not be influenced. The preparation process of the granular agent has the advantages of simplicity and low cost.